nach oben

Erschienen in:

01.06.2024 | Original Paper

G₂C₄ targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons

verfasst von: Jeffrey D. Rothstein, Victoria Baskerville, Sampath Rapuri, Emma Mehlhop, Paymaan Jafar-Nejad, Frank Rigo, Frank Bennett, Sarah Mizielinska, Adrian Isaacs, Alyssa N. Coyne

Erschienen in: Acta Neuropathologica | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

The G₄C₂ repeat expansion in the C9orf72 gene is the most common genetic cause of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Many studies suggest that dipeptide repeat proteins produced from this repeat are toxic, yet, the contribution of repeat RNA toxicity is under investigated and even less is known regarding the pathogenicity of antisense repeat RNA. Recently, two clinical trials targeting G₄C₂ (sense) repeat RNA via antisense oligonucleotide failed despite a robust decrease in sense-encoded dipeptide repeat proteins demonstrating target engagement. Here, in this brief report, we show that G₂C₄ antisense, but not G₄C₂ sense, repeat RNA is sufficient to induce TDP-43 dysfunction in induced pluripotent stem cell (iPSC) derived neurons (iPSNs). Unexpectedly, only G₂C₄, but not G₄C₂ sense strand targeting, ASOs mitigate deficits in TDP-43 function in authentic C9orf72 ALS/FTD patient iPSNs. Collectively, our data suggest that the G₂C₄ antisense repeat RNA may be an important therapeutic target and provide insights into a possible explanation for the recent G₄C₂ ASO clinical trial failure.

Nur mit Berechtigung zugänglich

Aladesuyi Arogundade O, Stauffer JE, Saberi S, Diaz-Garcia S, Malik S, Basilim H et al (2019) Antisense RNA foci are associated with nucleoli and TDP-43 mislocalization in C9orf72-ALS/FTD: a quantitative study. Acta Neuropathol 137:527–530. https://doi.org/10.1007/s00401-018-01955-0CrossRefPubMed

Baskerville V, Rapuri S, Mehlhop E, Coyne AN (2023) SUN1 facilitates CHMP7 nuclear influx and injury cascades in sporadic amyotrophic lateral sclerosis. Brain. https://doi.org/10.1093/brain/awad291CrossRefPubMed

Baxi EG, Thompson T, Li J, Kaye JA, Lim RG, Wu J et al (2022) Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nat Neurosci 25:226–237. https://doi.org/10.1038/s41593-021-01006-0CrossRefPubMedPubMedCentral

Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC et al (2022) TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603:131–137. https://doi.org/10.1038/s41586-022-04436-3CrossRefPubMedPubMedCentral

Chew J, Cook C, Gendron TF, Jansen-West K, Del Rosso G, Daughrity LM et al (2019) Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol Neurodegener 14:9. https://doi.org/10.1186/s13024-019-0310-zCrossRefPubMedPubMedCentral

Conlon EG, Lu L, Sharma A, Yamazaki T, Tang T, Shneider NA et al (2016) The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. Elife. https://doi.org/10.7554/eLife.17820CrossRefPubMedPubMedCentral

Cooper-Knock J, Higginbottom A, Stopford MJ, Highley JR, Ince PG, Wharton SB et al (2015) Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. Acta Neuropathol 130:63–75. https://doi.org/10.1007/s00401-015-1429-9CrossRefPubMedPubMedCentral

Coyne AN, Baskerville V, Zaepfel BL, Dickson DW, Rigo F, Bennett F et al (2021) Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Sci Transl Med. https://doi.org/10.1126/scitranslmed.abe1923CrossRefPubMedPubMedCentral

Coyne AN, Zaepfel BL, Hayes L, Fitchman B, Salzberg Y, Luo EC et al (2020) G(4)C(2) Repeat RNA Initiates a POM121-Mediated Reduction in Specific Nucleoporins in C9orf72 ALS/FTD. Neuron. https://doi.org/10.1016/j.neuron.2020.06.027CrossRefPubMedPubMedCentral

10.

Davidson YS, Barker H, Robinson AC, Thompson JC, Harris J, Troakes C et al (2014) Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun 2:70. https://doi.org/10.1186/2051-5960-2-70CrossRefPubMedPubMedCentral

11.

DeJesus-Hernandez M, Finch NA, Wang X, Gendron TF, Bieniek KF, Heckman MG et al (2017) In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathol 134:255–269. https://doi.org/10.1007/s00401-017-1725-7CrossRefPubMedPubMedCentral

12.

DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245–256. https://doi.org/10.1016/j.neuron.2011.09.011CrossRefPubMedPubMedCentral

13.

DeVos SL, Miller TM (2013) Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics 10:486–497. https://doi.org/10.1007/s13311-013-0194-5CrossRefPubMedPubMedCentral

14.

Donnelly CJ, Zhang PW, Pham JT, Haeusler AR, Mistry NA, Vidensky S et al (2013) RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80:415–428. https://doi.org/10.1016/j.neuron.2013.10.015CrossRefPubMedPubMedCentral

15.

Freibaum BD, Taylor JP (2017) The Role of Dipeptide Repeats in C9ORF72-Related ALS-FTD. Front Mol Neurosci 10:35. https://doi.org/10.3389/fnmol.2017.00035CrossRefPubMedPubMedCentral

16.

Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, Caulfield T et al (2013) Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol 126:829–844. https://doi.org/10.1007/s00401-013-1192-8CrossRefPubMedPubMedCentral

17.

Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M et al (2017) Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aai7866CrossRefPubMedPubMedCentral

18.

Gitler AD, Tsuiji H (2016) There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS. Brain Res 1647:19–29. https://doi.org/10.1016/j.brainres.2016.04.004CrossRefPubMedPubMedCentral

19.

Gleixner AM, Verdone BM, Otte CG, Anderson EN, Ramesh N, Shapiro OR et al (2022) NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility. Nat Commun 13:3380. https://doi.org/10.1038/s41467-022-31098-6CrossRefPubMedPubMedCentral

20.

Gupta R, Lan M, Mojsilovic-Petrovic J, Choi WH, Safren N, Barmada S et al (2017) The Proline/Arginine Dipeptide from Hexanucleotide Repeat Expanded C9ORF72 Inhibits the Proteasome. eNeuro. https://doi.org/10.1523/eneuro.0249-16.2017CrossRefPubMedPubMedCentral

21.

Irwin KE, Jasin P, Braunstein KE, Sinha I, Bowden KD, Moghekar A et al (2023) A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS. bioRxiv. https://doi.org/10.1101/2023.01.23.525202CrossRefPubMedPubMedCentral

22.

Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A et al (2016) Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron 90:535–550. https://doi.org/10.1016/j.neuron.2016.04.006CrossRefPubMedPubMedCentral

23.

Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA et al (2019) ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci 22:167–179. https://doi.org/10.1038/s41593-018-0300-4CrossRefPubMedPubMedCentral

24.

Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR et al (2013) Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A 110:E4530-4539. https://doi.org/10.1073/pnas.1318835110CrossRefPubMedPubMedCentral

25.

Lee SM, Asress S, Hales CM, Gearing M, Vizcarra JC, Fournier CN et al (2019) TDP-43 cytoplasmic inclusion formation is disrupted in C9orf72-associated amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Brain Commun. https://doi.org/10.1093/braincomms/fcz014CrossRefPubMedPubMedCentral

26.

Lee YB, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar M et al (2013) Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep 5:1178–1186. https://doi.org/10.1016/j.celrep.2013.10.049CrossRefPubMedPubMedCentral

27.

Lin Y, Mori E, Kato M, Xiang S, Wu L, Kwon I et al (2016) Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers. Cell 167:789-802.e712. https://doi.org/10.1016/j.cell.2016.10.003CrossRefPubMedPubMedCentral

28.

Ling JP, Pletnikova O, Troncoso JC, Wong PC (2015) TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349:650–655. https://doi.org/10.1126/science.aab0983CrossRefPubMedPubMedCentral

29.

Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR et al (2016) C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron 90:521–534. https://doi.org/10.1016/j.neuron.2016.04.005CrossRefPubMed

30.

Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F et al (2022) TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature 603:124–130. https://doi.org/10.1038/s41586-022-04424-7CrossRefPubMedPubMedCentral

31.

Mackenzie IR, Frick P, Neumann M (2014) The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol 127:347–357. https://doi.org/10.1007/s00401-013-1232-4CrossRefPubMed

32.

Melamed Z, López-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y et al (2019) Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci 22:180–190. https://doi.org/10.1038/s41593-018-0293-zCrossRefPubMedPubMedCentral

33.

Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A et al (2014) C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345:1192–1194. https://doi.org/10.1126/science.1256800CrossRefPubMedPubMedCentral

34.

Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P et al (2013) C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol 126:845–857. https://doi.org/10.1007/s00401-013-1200-zCrossRefPubMedPubMedCentral

35.

Moens TG, Mizielinska S, Niccoli T, Mitchell JS, Thoeng A, Ridler CE et al (2018) Sense and antisense RNA are not toxic in Drosophila models of C9orf72-associated ALS/FTD. Acta Neuropathol 135:445–457. https://doi.org/10.1007/s00401-017-1798-3CrossRefPubMedPubMedCentral

36.

Nana AL, Sidhu M, Gaus SE, Hwang JL, Li L, Park Y et al (2019) Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol 137:27–46. https://doi.org/10.1007/s00401-018-1942-8CrossRefPubMed

37.

Prudencio M, Humphrey J, Pickles S, Brown AL, Hill SE, Kachergus J et al (2020) Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. https://doi.org/10.1172/jci139741CrossRefPubMedPubMedCentral

38.

Prudencio M, Jansen-West KR, Lee WC, Gendron TF, Zhang YJ, Xu YF et al (2012) Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. Proc Natl Acad Sci U S A 109:21510–21515. https://doi.org/10.1073/pnas.1211577110CrossRefPubMedPubMedCentral

39.

Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268. https://doi.org/10.1016/j.neuron.2011.09.010CrossRefPubMedPubMedCentral

40.

Roczniak-Ferguson A, Ferguson SM (2019) Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis. Life Sci Allian https://doi.org/10.26508/lsa.201900358

41.

Sareen D, O’Rourke JG, Meera P, Muhammad AK, Grant S, Simpkinson M et al (2013) Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. https://doi.org/10.1126/scitranslmed.3007529CrossRefPubMedPubMedCentral

42.

Schoch KM, Miller TM (2017) Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases. Neuron 94:1056–1070. https://doi.org/10.1016/j.neuron.2017.04.010CrossRefPubMedPubMedCentral

43.

Seddighi S, Qi YA, Brown A-L, Wilkins OG, Bereda C, Belair C et al (2023) Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD. bioRxiv. https://doi.org/10.1101/2023.01.23.525149CrossRefPubMedPubMedCentral

44.

Vatsavayai SC, Nana AL, Yokoyama JS, Seeley WW (2019) C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. Acta Neuropathol 137:1–26. https://doi.org/10.1007/s00401-018-1921-0CrossRefPubMed

45.

Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A et al (2016) Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain 139:3202–3216. https://doi.org/10.1093/brain/aww250CrossRefPubMedPubMedCentral

46.

Wen X, Tan W, Westergard T, Krishnamurthy K, Markandaiah SS, Shi Y et al (2014) Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84:1213–1225. https://doi.org/10.1016/j.neuron.2014.12.010CrossRefPubMedPubMedCentral

47.

Yuva-Aydemir Y, Almeida S, Krishnan G, Gendron TF, Gao FB (2019) Transcription elongation factor AFF2/FMR2 regulates expression of expanded GGGGCC repeat-containing C9ORF72 allele in ALS/FTD. Nat Commun 10:5466. https://doi.org/10.1038/s41467-019-13477-8CrossRefPubMedPubMedCentral

48.

Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P et al (2015) The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525:56–61. https://doi.org/10.1038/nature14973CrossRefPubMedPubMedCentral

49.

Zhang YJ, Guo L, Gonzales PK, Gendron TF, Wu Y, Jansen-West K et al (2019) Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science. https://doi.org/10.1126/science.aav2606CrossRefPubMedPubMedCentral

Titel: G2C4 targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons
verfasst von: Jeffrey D. Rothstein
Victoria Baskerville
Sampath Rapuri
Emma Mehlhop
Paymaan Jafar-Nejad
Frank Rigo
Frank Bennett
Sarah Mizielinska
Adrian Isaacs
Alyssa N. Coyne
Publikationsdatum: 01.06.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Acta Neuropathologica / Ausgabe 1/2024
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-023-02652-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

G₂C₄ targeting antisense oligonucleotides potently mitigate TDP-43 dysfunction in human C9orf72 ALS/FTD induced pluripotent stem cell derived neurons

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Role of GBA variants in Lewy body disease neuropathology

Characterisation of premature cell senescence in Alzheimer’s disease using single nuclear transcriptomics

Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer’s disease and related dementias

Regulated cell death and its role in Alzheimer’s disease and amyotrophic lateral sclerosis

Disentangling and quantifying the relative cognitive impact of concurrent mixed neurodegenerative pathologies

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Update Neurologie